A Phase 1 interventional study of MC2-01 Cream and Clobetasol Propionate 0.05% Lotion in Vasoconstriction, sponsored by MC2 Therapeutics. Completed at 1 site in France. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-01-09.
Sponsored by MC2 Therapeutics · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The objective of this trial is to compare the vasoconstriction potential
The objective of this trial is to compare the vasoconstriction potential (skin blanching effect) of MC2-01 cream with 5 comparators and MC2-01 vehicle using the human skin blanching test (McKenzie-Stoughton's test).
MC2 Therapeutics is the lead sponsor of 9 studies on the registry; none are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 7 (100%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single application of MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
Drug: MC2-01 Cream
Single application of Clobetasol propionate 0.05%,
Drug: Clobetasol Propionate 0.05% Lotion
Single application of Betamethasone dipropionate 0.05%,
Drug: Betamethasone Dipropionate 0.05% Cream
Single application of Triamcinolone acetonide 0.1%,
Drug: Triamcinolone Acetonide 0.1% Cream
Single application of Hydrocortisone Butyrate 0.1% Cream
Drug: Hydrocortisone Butyrate 0.1% Cream
Single application of Desonide 0.05%
Drug: Desonide 0.05% Cream
Single application of Vehicle
Drug: Vehicle
Drug pages: Calcipotriene · Betamethasone dipropionate
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Also known as: Calcipotriol + Betamethasone dipropionate cream
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Also known as: Clobex
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Also known as: Betamethasone Dipropionate
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Also known as: Triamcinolone acetonide
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Also known as: Locoid® cream
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Also known as: Desowen® cream
Single application, visual evaluation of skin blanching and local tolerability, physical examination and safety evaluation
Also known as: Vehicle cream
Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle
Blanching of the skin will be assessed individually by two trained observers blinded to treatment. The observers will score the blanching of the skin from 0-4 (0 = No change in color skin; 1 = Slight (barely visible) blanching; 3 = Obvious blanching; 4 = Blanching judged to be maximal). The results is presented as Mean ± SD.
Time frame: Day 2
Compare Local Tolerability of the MC2-01 Cream With Active Comparators and Vehicle
The local tolerability of the creams will be assesed using a predefined scale: 0 = No reaction; 0.5 = Only slight erythema; 1 = Only erythema; 2 = Erythema with papules or oedema; 3 = Erythema, oedema with papules, oedema with vesicle; 4 = Blisters
Time frame: Day 2
First Subject First Visit: 07-Nov-2018. Last Subject Last Visit: 23-Nov-2018
| Milestone | MC2-01 Cream + Comparators |
|---|---|
| Started | 36 |
| Mc2-01 cream | 36 |
| Clobetasol propionate 0.05% lotion | 36 |
| Betamethasone dipropionate 0.05% cream | 36 |
| Triamcinolone acetonide 0,1% cream | 36 |
| Hydrocortisone butyrate 0.1% cream | 36 |
| Desonide 0.05% cream | 36 |
| Vehicle cream | 36 |
| Completed | 36 |
| Not completed | 0 |
Blanching of the skin will be assessed individually by two trained observers blinded to treatment. The observers will score the blanching of the skin from 0-4 (0 = No change in color skin; 1 = Slight (barely visible) blanching; 3 = Obvious blanching; 4 = Blanching judged to be maximal). The results is presented as Mean ± SD.
| score on a scale | MC2-01 Cream + Comparators |
|---|---|
| MC2-01 Cream | 1.66 ± 0.57 |
| Clobetasol Propionate 0.05% Lotion | 3.05 ± 0.65 |
| Betamethasone Dipropionate 0.05% Cream | 2.45 ± 0.61 |
| Triamcinolone Acetonide 0.1% Cream | 1.92 ± 0.89 |
| Hydrocortisone Butyrate 0.1% Cream | 2.06 ± 0.70 |
| Desonide 0.05% Cream | 2.11 ± 0.85 |
| Vehicle Cream | 0.14 ± 0.25 |
The local tolerability of the creams will be assesed using a predefined scale: 0 = No reaction; 0.5 = Only slight erythema; 1 = Only erythema; 2 = Erythema with papules or oedema; 3 = Erythema, oedema with papules, oedema with vesicle; 4 = Blisters
| Participants | MC2-01 Cream + Comparators |
|---|---|
| MC2-01 Cream — No reaction | 36 |
| MC2-01 Cream — Only Slight reaction | 0 |
| MC2-01 Cream — Only erythema | 0 |
| MC2-01 Cream — Erythema with papules or oedema | 0 |
| MC2-01 Cream — Erythema, oedema with papules, oedema with vesicle | 0 |
| MC2-01 Cream — Blisters | 0 |
| Clobetasol Propionate 0.05% Lotion — No reaction | 36 |
| Clobetasol Propionate 0.05% Lotion — Only Slight reaction | 0 |
| Clobetasol Propionate 0.05% Lotion — Only erythema | 0 |
| Clobetasol Propionate 0.05% Lotion — Erythema with papules or oedema | 0 |
| Clobetasol Propionate 0.05% Lotion — Erythema, oedema with papules, oedema with vesicle | 0 |
| Clobetasol Propionate 0.05% Lotion — Blisters | 0 |
| Betamethasone Dipropionate 0.05% Cream — No reaction | 36 |
| Betamethasone Dipropionate 0.05% Cream — Only Slight reaction | 0 |
| Betamethasone Dipropionate 0.05% Cream — Only erythema | 0 |
| Betamethasone Dipropionate 0.05% Cream — Erythema with papules or oedema | 0 |
| Betamethasone Dipropionate 0.05% Cream — Erythema, oedema with papules, oedema with vesicle | 0 |
| Betamethasone Dipropionate 0.05% Cream — Blisters | 0 |
| Triamcinolone Acetonide 0.1% Cream — No reaction | 36 |
| Triamcinolone Acetonide 0.1% Cream — Only Slight reaction | 0 |
| Triamcinolone Acetonide 0.1% Cream — Only erythema | 0 |
| Triamcinolone Acetonide 0.1% Cream — Erythema with papules or oedema | 0 |
| Triamcinolone Acetonide 0.1% Cream — Erythema, oedema with papules, oedema with vesicle | 0 |
| Triamcinolone Acetonide 0.1% Cream — Blisters | 0 |
| Hydrocortisone Butyrate 0.1% Cream — No reaction | 36 |
| Hydrocortisone Butyrate 0.1% Cream — Only Slight reaction | 0 |
| Hydrocortisone Butyrate 0.1% Cream — Only erythema | 0 |
| Hydrocortisone Butyrate 0.1% Cream — Erythema with papules or oedema | 0 |
| Hydrocortisone Butyrate 0.1% Cream — Erythema, oedema with papules, oedema with vesicle | 0 |
| Hydrocortisone Butyrate 0.1% Cream — Blisters | 0 |
| Desonide 0.05% Cream — No reaction | 36 |
| Desonide 0.05% Cream — Only Slight reaction | 0 |
| Desonide 0.05% Cream — Only erythema | 0 |
| Desonide 0.05% Cream — Erythema with papules or oedema | 0 |
| Desonide 0.05% Cream — Erythema, oedema with papules, oedema with vesicle | 0 |
| Desonide 0.05% Cream — Blisters | 0 |
| Vehicle Cream — No reaction | 36 |
| Vehicle Cream — Only Slight reaction | 0 |
| Vehicle Cream — Only erythema | 0 |
| Vehicle Cream — Erythema with papules or oedema | 0 |
| Vehicle Cream — Erythema, oedema with papules, oedema with vesicle | 0 |
| Vehicle Cream — Blisters | 0 |
Collected over AEs were collected/assessed from the time the informed consent form was signed at the screening visit, which could occur up to 14 days prior to the test period, during the 2 day's test period and until the follow-up visit, 15 days following the test period, had occurred. AEs assessed as reasonably possibly related to the trial medication had to be followed until they were resolved or until the medical condition of the subject was stable.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MC2-01 Cream | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Clobetasol Propionate 0.05% Lotion | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Betamethasone Dipropionate 0.05% Cream | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Triamcinolone Acetonide 0.1% Cream | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Hydrocortisone Butyrate 0.1% Cream | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Desonide 0.05% Cream | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
| Vehicle Cream | 0/36 (0%) | 0/36 (0%) | 0/36 (0%) |
All patients received all 7 types of treatments.
| Age, Continuous(years) | MC2-01 Cream + Comparators |
|---|---|
| Mean | 34.36 ± 6.57 |
| Sex: Female, Male(Participants) | MC2-01 Cream + Comparators |
|---|---|
| Female | 28 |
| Male | 8 |
| Race and Ethnicity Not Collected(Participants) | MC2-01 Cream + Comparators |
|---|
| Region of Enrollment(participants) | MC2-01 Cream + Comparators |
|---|---|
| France | 36 |
| Fitzpatrick Skin Type(Participants) | MC2-01 Cream + Comparators |
|---|---|
| I | 0 |
| II | 9 |
| III | 24 |
| IV | 3 |
| V | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Single site study
Ran from Nov 2018 to primary completion in Nov 2018, 0 months.
Results were first posted in Jan 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Calcipotriene · Betamethasone dipropionate
MC2 Therapeutics